FTD SARS-CoV-2 Assay

For the specific detection of the coronavirus causing COVID-19 using RT-PCR

The FTDTM SARS-CoV-2 Assay1 is a qualitative in vitro nucleic acid amplification test for the detection of severe respiratory syndrome coronavirus 2 (SARS-CoV-2) nucleic acids in nasopharyngeal and oropharyngeal swabs of patients with signs and symptoms of SARS-CoV-2 infection in conjunction with clinical and epidemiological risk factors, who are suspected of Coronavirus Disease 2019 (COVID-19). The test is intended as an aid in the diagnosis of infections caused by the new human coronavirus SARS-CoV-2.

Clinical Use

In late 2019, China notified the World Health Organization (WHO) of a novel strain of coronavirus. This virus, now named SARS-CoV-2, targets the epithelial cells of the respiratory tract and causes infection that can lead to Coronavirus disease 2019 (COVID-19). Siemens Healthineers automated molecular assay uses real-time PCR to detect RNA from this virus.

Variant key visual image

As part of our ongoing Global Surveillance Program, the FTD SARS-CoV-2 Assay1 has been shown to detect emergent SARS-CoV-2 variants.

View the results of in silico analysis to learn more! 

Explore our dual-target design for the detection of SARS-CoV-2

Features & Benefits

  • RT-PCR kit comprised of a single-well dual target assay for the specific detection of SARS-CoV-2 (COVID-19)
  • Designed for high sensitivity, specificity, and inclusivity*
  • Covers highly conserved regions within ORF1ab and N gene
  • Uses the same assay setup protocol and thermal-cycling profile as all FTD respiratory disease kits